UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043910
Receipt number R000049020
Scientific Title Association between brain atrophy and intestinal permeability in patients with multiple sclerosis
Date of disclosure of the study information 2021/06/01
Last modified on 2024/04/15 12:28:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association between brain atrophy and intestinal permeability in patients with multiple sclerosis

Acronym

Brain atrophy and intestinal permeability in MS

Scientific Title

Association between brain atrophy and intestinal permeability in patients with multiple sclerosis

Scientific Title:Acronym

Brain atrophy and intestinal permeability in MS

Region

Japan


Condition

Condition

multiple sclerosis

Classification by specialty

Neurology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine the association between the rate of brain atrophy and intestinal permeability in patients with MS

Basic objectives2

Others

Basic objectives -Others

association

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Correlation between the rate of brain atrophy over 48 months and intestinal permeability measured at baseline.

Key secondary outcomes

Association between intestinal permeability at baseline and disease subtypes, disability, cognition, brain volume and disease modifying therapy


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine

Interventions/Control_1

A standard solution of lactulose (5 g) and mannitol (2 g)in 500 mL of tap water was ingested before bed. Urine was collected the following morning in a container (with 5 mL of thymol solution).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

MS and related disorders (neuromyelitis optica spectrum disorders (NMOSD) and clinically isolated sydrome) will be included. MS is diagnosed by McDonald's criteria 2017 and NMOSD is diagnosed by Wingerchuk's criteria 2015.

Key exclusion criteria

Persons who have
1. pace makers or magnetic metals
2. claustrophobia
3. unstable general condition and vital signs
4. difficulty in informed consent
5. cancers or inflammatory bowel disease
6. diabetes mellitus
, pregnant women and persons who is not suitable for the participants according to the doctor's decision.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Yoichiro
Middle name
Last name Nishida

Organization

Tokyo Medical and Dental University

Division name

Department of Neurology

Zip code

1648607

Address

1-5-45, Yushima, Bunkyo-ku, Tokyo

TEL

0358035234

Email

yktenuro@gmail.com


Public contact

Name of contact person

1st name Hiroaki
Middle name
Last name Yokote

Organization

Nitobe Memorial Nakano General Hospital

Division name

Department of Neurology

Zip code

1648607

Address

4-59-16, Chuo, Nakano-ku, Tokyo

TEL

0333821231

Homepage URL


Email

yktenuro@gmail.com


Sponsor or person

Institute

Department of Neurology and Neurological Science, Tokyo Medical and Dental University

Institute

Department

Personal name



Funding Source

Organization

The Japanese society for neuroimmunology

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokyo Medical and Dental Univeristy

Address

1-5-45, Yushima, Bunkyo-ku, Tokyo

Tel

0333821231

Email

yktenuro@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2021 Year 04 Month 13 Day

Date of IRB

2021 Year 04 Month 13 Day

Anticipated trial start date

2021 Year 06 Month 01 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 04 Month 13 Day

Last modified on

2024 Year 04 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049020


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name